Thus, these advances have paved the way for large (pre)-clinical studies to investigate tubular reabsorption of hepcidin in various clinical disorders, especially in anemias that are associated with renal diseases where hepcidin is predicted to be an important contributor [34]. This evidence concerns the gene HAMP and anemia.